Hepion Pharmaceuticals (HEPA) Competitors $0.06 0.00 (-5.00%) As of 03:58 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock HEPA vs. PTN, JAGX, APVO, ENTO, SCNI, SXTP, PTIX, GRTX, ONCO, and AKANShould you be buying Hepion Pharmaceuticals stock or one of its competitors? The main competitors of Hepion Pharmaceuticals include Palatin Technologies (PTN), Jaguar Animal Health (JAGX), Aptevo Therapeutics (APVO), Entero Therapeutics (ENTO), Scinai Immunotherapeutics (SCNI), 60 Degrees Pharmaceuticals (SXTP), Atrinsic (PTIX), Galera Therapeutics (GRTX), Onconetix (ONCO), and Akanda (AKAN). These companies are all part of the "pharmaceutical products" industry. Hepion Pharmaceuticals vs. Its Competitors Palatin Technologies Jaguar Animal Health Aptevo Therapeutics Entero Therapeutics Scinai Immunotherapeutics 60 Degrees Pharmaceuticals Atrinsic Galera Therapeutics Onconetix Akanda Palatin Technologies (NYSE:PTN) and Hepion Pharmaceuticals (NASDAQ:HEPA) are both small-cap pharmaceutical preparations industry companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends. Which has more volatility & risk, PTN or HEPA? Palatin Technologies has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500. Comparatively, Hepion Pharmaceuticals has a beta of 1.69, indicating that its share price is 69% more volatile than the S&P 500. Does the media refer more to PTN or HEPA? In the previous week, Palatin Technologies' average media sentiment score of 0.00 equaled Hepion Pharmaceuticals'average media sentiment score. Company Overall Sentiment Palatin Technologies Neutral Hepion Pharmaceuticals Neutral Which has preferable valuation & earnings, PTN or HEPA? Palatin Technologies has higher revenue and earnings than Hepion Pharmaceuticals. Palatin Technologies is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPalatin Technologies$350K6.99-$40.31M-$1.55-0.06Hepion PharmaceuticalsN/AN/A-$48.93M-$219.000.00 Is PTN or HEPA more profitable? Palatin Technologies' return on equity of 0.00% beat Hepion Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Palatin TechnologiesN/A N/A N/A Hepion Pharmaceuticals N/A -812.56%-207.31% Do insiders & institutionals have more ownership in PTN or HEPA? 11.5% of Palatin Technologies shares are held by institutional investors. Comparatively, 17.2% of Hepion Pharmaceuticals shares are held by institutional investors. 7.1% of Palatin Technologies shares are held by insiders. Comparatively, 0.1% of Hepion Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryPalatin Technologies beats Hepion Pharmaceuticals on 6 of the 9 factors compared between the two stocks. Get Hepion Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for HEPA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HEPA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HEPA vs. The Competition Export to ExcelMetricHepion PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$623K$776.90M$5.70B$9.51BDividend YieldN/A4.84%4.69%4.01%P/E Ratio-0.011.4028.0720.06Price / SalesN/A25.35449.2099.44Price / CashN/A19.5636.2258.56Price / Book0.046.798.665.87Net Income-$48.93M-$4.32M$3.25B$258.55M7 Day PerformanceN/A1.33%4.20%2.23%1 Month PerformanceN/A3.74%10.82%12.76%1 Year PerformanceN/A8.18%34.70%19.36% Hepion Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HEPAHepion Pharmaceuticals0.1265 of 5 stars$0.06-5.0%N/A-99.8%$623KN/A-0.0120Gap UpPTNPalatin TechnologiesN/A$0.09-44.6%N/AN/A$2.45M$350K-0.0630Gap DownHigh Trading VolumeJAGXJaguar Animal Health2.8842 of 5 stars$2.41+3.9%$60.00+2,389.6%-93.4%$2.36M$11.69M0.0050Gap UpHigh Trading VolumeAPVOAptevo Therapeutics2.4959 of 5 stars$3.05+0.7%$219,040.00+7,181,539.3%-100.0%$2.29M$3.11M0.0050ENTOEntero TherapeuticsN/A$0.49+4.2%N/A-51.6%$2.25MN/A0.009SCNIScinai Immunotherapeutics1.7665 of 5 stars$2.20+2.3%N/A-50.0%$2.15M$658K-0.2320SXTP60 Degrees Pharmaceuticals2.8203 of 5 stars$1.39-3.5%$7.00+403.6%+51.7%$2.12M$300K-0.033PTIXAtrinsic0.5198 of 5 stars$3.18-7.0%N/A-69.0%$2.01MN/A-0.242GRTXGalera TherapeuticsN/A$0.03+1.2%N/A-80.6%$1.92MN/A-0.0730ONCOOnconetix0.3214 of 5 stars$3.80+10.5%N/A-99.3%$1.83M$1.93M0.0012Gap UpHigh Trading VolumeAKANAkanda1.1474 of 5 stars$1.24+2.1%N/A-60.9%$1.73M$840K0.00110 Related Companies and Tools Related Companies PTN Alternatives JAGX Alternatives APVO Alternatives ENTO Alternatives SCNI Alternatives SXTP Alternatives PTIX Alternatives GRTX Alternatives ONCO Alternatives AKAN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HEPA) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hepion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hepion Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HEPA Stock Alerts